CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported the presentation of results from a phase 2 trial evaluating MLN8237, an investigational inhibitor of Aurora A kinase, in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma (NHL). Also presented were biomarker data from a phase 3 study comparing VELCADE® (bortezomib) and rituximab (VcR) to rituximab (R) alone in patients with relapsed or refractory follicular lymphoma (FL). These data were presented during oral presentations at the 53rd annual meeting of the American Society of Hematology (ASH), held December 10th – 13th in San Diego, California.
